| Second-line chemotherapy for non-small-cell lung cancer: recent data with pemetrexed. | |
| | |
MedLine Citation:
|
PMID: 15117429 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Platinum-based chemotherapy offers a modest survival advantage over best supportive care (BSC) in chemotherapy-naive patients with a good performance status and advanced/metastatic non-small-cell lung cancer (NSCLC). Based on 2 landmark studies that reported improved survival times and quality of life when comparing docetaxel with ifosfamide, vinorelbine, or BSC alone, docetaxel at 75 mg/m(2) given once every 3 weeks has been the standard of care as second-line chemotherapy since 2000. Docetaxel given at this dose and schedule resulted in significant hematologic toxicity, with many patients at risk for neutropenic fever. Pemetrexed is a novel multitargeted antifolate agent with single-agent activity in first- and second-line treatment of NSCLC. A phase III study in 571 patients comparing pemetrexed with docetaxel demonstrated clinically equivalent therapeutic outcomes in second-line treatment of patients with recurrent NSCLC; however, patients on the pemetrexed arm had a more favorable hematologic toxicity profile, with fewer episodes of neutropenia, neutropenic fever, and infections and less use of granulocyte colony-stimulating factor support. Based on these data, pemetrexed is a reasonable second-line chemotherapy option for patients with recurrent, advanced NSCLC. |
| | |
Authors:
|
Nasser H Hanna |
Related Documents
:
|
20890069 - Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of p... 10631469 - A phase i-ii study of gemcitabine and docetaxel in advanced pancreatic cancer: a report... 16368869 - Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. 16127289 - Phase i study of weekly docetaxel and liposomal doxorubicin in patients with advanced s... 15078909 - Weekly administration of docetaxel in patients with hormone-refractory prostate cancer:... 21084429 - Phase iii trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with p... 8763849 - The in situ tumour response to combinations of cyclophosphamide and tirapazamine. 19402079 - Long-term follow-up results of fertility sparing surgery in patients with epithelial ov... 22180399 - Follow-up with ca125 after primary therapy of advanced ovarian cancer has major implica... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Clinical lung cancer Volume: 5 Suppl 2 ISSN: 1525-7304 ISO Abbreviation: Clin Lung Cancer Publication Date: 2004 Apr |
Date Detail:
|
Created Date: 2004-04-30 Completed Date: 2004-09-02 Revised Date: 2008-12-12 |
Medline Journal Info:
|
Nlm Unique ID: 100893225 Medline TA: Clin Lung Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: S75-9 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Indiana University, Indianapolis 46202, USA. nhanna@iupui.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
therapeutic use* Carcinoma, Non-Small-Cell Lung / drug therapy* Clinical Trials as Topic Dose-Response Relationship, Drug Drug Administration Schedule Glutamates / therapeutic use* Guanine / analogs & derivatives*, therapeutic use* Humans Lung Neoplasms / drug therapy* Neoplasm Recurrence, Local / drug therapy* Taxoids / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Glutamates; 0/Taxoids; 114977-28-5/docetaxel; 137281-23-3/pemetrexed; 73-40-5/Guanine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data.
Next Document: Information management and informatics: need for a modern pathology service.